The role of cannabinoid 1 receptor expressing interneurons in behavior

Neurobiology of Disease

Volumn 63, Issue , 2014, Pages 210-221

  Brown, Jacquelyn A ^a   Horváth, Szatmár ^a,b   Garbett, Krassimira A ^a   Schmidt, Martin J ^c   Everheart, Monika ^a   Gellért, Levente ^b   Ebert, Philip ^a   Mirnics, Károly ^a,b,d  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF SZEGED   (Hungary)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amphetamine; Behavior; Cnr1; Dopamine; Gad1; GAD67; Interneuron; MiRNA; Schizophrenia; Serotonin; Transgenic

Indexed keywords

CANNABINOID 1 RECEPTOR; MESSENGER RNA; MICRORNA;

ADULT; AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUDITORY RESPONSE; BEHAVIOR CHANGE; CONTROLLED STUDY; FEAR; GABAERGIC SYSTEM; GAD1 GENE; GENE; GENE SILENCING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERNEURON; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SOCIAL INTERACTION; TRANSGENIC MOUSE; WORKING MEMORY;

AMPHETAMINE; BEHAVIOR; CNR1; DOPAMINE; GAD1; GAD67; INTERNEURON; MIRNA; SCHIZOPHRENIA; SEROTONIN; TRANSGENIC;

AMPHETAMINE; ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CONDITIONING (PSYCHOLOGY); CYCLOHEXANOLS; EXPLORATORY BEHAVIOR; GLUTAMATE DECARBOXYLASE; INTERNEURONS; LOCOMOTION; MICE; MICE, TRANSGENIC; MUTATION; NEUROPEPTIDE Y; RECEPTOR, CANNABINOID, CB1; RNA, MESSENGER; SENSORY GATING;

EID: 84891701559     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.11.001     Document Type: Article

References (83)

1. Abi-Dargham A., et al. The role of serotonin in the pathophysiology and treatment of schizophrenia. J. Neuropsychiatry Clin. Neurosci. 1997, 9:1-17.
2. Amano T., et al. The fear circuit revisited: contributions of the basal amygdala nuclei to conditioned fear. J. Neurosci. 2011, 31:15481-15489.
3. Andreasson S., et al. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987, 2:1483-1486.
4. Arevalo C., et al. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol. Biochem. Behav. 2001, 70:123-131.
5. Arseneault L., et al. Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry 2004, 184:110-117.
6. Beierlein M., Regehr W.G. Local interneurons regulate synaptic strength by retrograde release of endocannabinoids. J. Neurosci. 2006, 26:9935-9943.
7. Bhattacharyya S., et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010, 35:764-774.
8. Bizzarri J.V., et al. Substance use in severe mental illness: self-medication and vulnerability factors. Psychiatry Res. 2009, 165:88-95.
9. Bloomfield M.A., et al. Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol. Psychiatry 2013 Jun 29, (pii: S0006-3223(13)00502-7, Epub ahead of print, PMID:23820822). 10.1016/j.biopsych.2013.05.027.
10. Bortolato M., et al. The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. Psychopharmacology 2005, 177:264-271.
11. Buchmayer F., et al. Amphetamine actions at the serotonin transporter rely on the availability of phosphatidylinositol-4,5-bisphosphate. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:11642-11647.
12. Curley A.A., et al. Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features. Am. J. Psychiatry 2011, 168:921-929.
13. de Bartolomeis A., et al. Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins. Psychopharmacology (Berl.) 2013, 225:1-19.
14. Dixon L., et al. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am. J. Psychiatry 1991, 148:224-230.
15. Drew W.G., et al. Effects of delta9-THC, LSD-25 and scopolamine on continuous, spontaneous alternation in the Y-maze. Psychopharmacologia 1973, 32:171-182.
16. Eggan S.M., et al. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch. Gen. Psychiatry 2008, 65:772-784.
17. Eggan S.M., et al. Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience 2010, 169:1651-1661.
18. Eggan S.M., et al. Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology 2010, 35:2060-2071.
19. Ehrlich I., et al. Amygdala inhibitory circuits and the control of fear memory. Neuron 2009, 62:757-771.
20. Evins A.E., et al. Does using marijuana increase the risk for developing schizophrenia?. J. Clin. Psychiatry 2013, 74:e08.
21. Galici R., et al. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J. Pharmacol. Exp. Ther. 2005, 315:1181-1187.
22. Galve-Roperh I., et al. Mechanisms of control of neuron survival by the endocannabinoid system. Curr. Pharm. Des. 2008, 14:2279-2288.
23. Ganon-Elazar E., Akirav I. Cannabinoid receptor activation in the basolateral amygdala blocks the effects of stress on the conditioning and extinction of inhibitory avoidance. J. Neurosci. 2009, 29:11078-11088.
24. Garbett K.A., et al. Novel animal models for studying complex brain disorders: BAC-driven miRNA-mediated in vivo silencing of gene expression. Mol. Psychiatry 2010, 15:987-995.
25. Gong S., Yang X.W. Modification of bacterial artificial chromosomes (BACs) and preparation of intact BAC DNA for generation of transgenic mice. Curr. Protoc. Neurosci 2005 May, (Chapter 5:Unit 5.21, PMID:18428623). 10.1002/0471142301.ns0521s31.
26. Goswami S., et al. Substance-abusing schizophrenics: do they self-medicate?. Am. J. Addict. 2004, 13:139-150.
27. Guidotti A., et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch. Gen. Psychiatry 2000, 57:1061-1069.
28. Hammond S.M. Dicing and slicing: the core machinery of the RNA interference pathway. FEBS Lett. 2005, 579:5822-5829.
29. Harkany T., et al. The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol. Sci. 2007, 28:83-92.
30. Hashimoto T., et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J. Neurosci. 2003, 23:6315-6326.
31. Henquet C., et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005, 330:11.
32. Hernandez L., et al. Simultaneous microdialysis and amphetamine infusion in the nucleus accumbens and striatum of freely moving rats: increase in extracellular dopamine and serotonin. Brain Res. Bull. 1987, 19:623-628.
33. Hillard C.J., et al. Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 2012, 204:207-229.
34. Horvath S., Mirnics K. Breaking the gene barrier in schizophrenia. Nat. Med. 2009, 15:488-490.
35. Impagnatiello F., et al. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:15718-15723.
36. Insel T.R. A neurobiological basis of social attachment. Am. J. Psychiatry 1997, 154:726-735.
37. Iqbal N., van Praag H.M. The role of serotonin in schizophrenia. Eur. Neuropsychopharmacol. 1995, 5:11-23. (Suppl.).
38. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry 1996, 153:466-476.
39. Katona I., Freund T.F. Multiple functions of endocannabinoid signaling in the brain. Annu. Rev. Neurosci. 2012, 35:529-558.
40. Katona I., et al. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 2000, 100:797-804.
41. Katona I., et al. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J. Neurosci. 2001, 21:9506-9518.
42. Katona I., et al. Molecular composition of the endocannabinoid system at glutamatergic synapses. J. Neurosci. 2006, 26:5628-5637.
43. Khantzian E.J. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv. Rev. Psychiatry 1997, 4:231-244.
44. Khoshbouei H., et al. N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol. 2004, 2:E78.
45. Kirkpatrick B., et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32:214-219.
46. Klausberger T., Somogyi P. Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operations. Science 2008, 321:53-57.
47. Kuczenski R., et al. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J. Neurosci. 1995, 15:1308-1317.
48. Litvin Y., et al. CB1 receptor signaling regulates social anxiety and memory. Genes Brain Behav. 2013, 12:479-489.
49. Marsicano G., Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur. J. Neurosci. 1999, 11:4213-4225.
50. Martin M., et al. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 2002, 159:379-387.
51. Matheson S.L., et al. A systematic meta-review grading the evidence for non-genetic risk factors and putative antecedents of schizophrenia. Schizophr. Res. 2011, 133:133-142.
52. Mirnics K., et al. Critical appraisal of DNA microarrays in psychiatric genomics. Biol. Psychiatry 2006, 60:163-176.
53. Misslin R., Ropartz P. Olfactory regulation of responsiveness to novelty in mice. Behav. Neural Biol. 1981, 33:230-236.
54. Monory K., et al. Genetic dissection of behavioural and autonomic effects of delta(9)-tetrahydrocannabinol in mice. PLoS Biol. 2007, 5:e269.
55. Morrison P.D., et al. The acute effects of synthetic intravenous delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol. Med. 2009, 39:1607-1616.
56. Mueser K.T., et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr. Bull. 1990, 16:31-56.
57. Mueser K.T., et al. Prevalence and stability of social skill deficits in schizophrenia. Schizophr. Res. 1991, 5:167-176.
58. Muller-Vahl K.R., Emrich H.M. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert. Rev. Neurother. 2008, 8:1037-1048.
59. Navailles S., De Deurwaerdere P. Presynaptic control of serotonin on striatal dopamine function. Psychopharmacology (Berl.) 2011, 213:213-242.
60. Pelayo-Teran J.M., et al. Gene-environment interactions underlying the effect of cannabis in first episode psychosis. Curr. Pharm. Des. 2012, 18:5024-5035.
61. Pereira C.W., et al. Electrolytic lesion of the nucleus incertus retards extinction of auditory conditioned fear. Behav. Brain Res. 2013, 247:201-210.
62. Pettit D.A., et al. Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J. Neurosci. Res. 1998, 51:391-402.
63. Phillips R.G., LeDoux J.E. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav. Neurosci. 1992, 106:274-285.
64. Rey A.A., et al. Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology 2012, 37:2624-2634.
65. Sah P., Westbrook R.F. Behavioural neuroscience: the circuit of fear. Nature 2008, 454:589-590.
66. Saito A., et al. Endocannabinoid system: potential novel targets for treatment of schizophrenia. Neurobiol. Dis. 2013, 53:10-17.
67. Schmidt M.J., Mirnics K. Modeling interneuron dysfunction in schizophrenia. Dev. Neurosci. 2012, 34:152-158.
68. Seillier A., et al. Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid cb1 receptors: implications for schizophrenia. Neuropsychopharmacology 2013, 38:1816-1824.
69. Smith D.R., et al. Genetic background differences and nonassociative effects in mouse trace fear conditioning. Learn. Mem. 2007, 14:597-605.
70. Tritsch N.X., Sabatini B.L. Dopaminergic modulation of synaptic transmission in cortex and striatum. Neuron 2012, 76:33-50.
71. Tsou K., et al. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998, 83:393-411.
72. Ujike H., et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol. Psychiatry 2002, 7:515-518.
73. van Os J., et al. Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 2002, 156:319-327.
74. Veen N.D., et al. Cannabis use and age at onset of schizophrenia. Am. J. Psychiatry 2004, 161:501-506.
75. Volk D.W., Lewis D.A. GABA targets for the treatment of cognitive dysfunction in schizophrenia. Curr. Neuropharmacol. 2005, 3:45-62.
76. Waltz J.A., Gold J.M. Probabilistic reversal learning impairments in schizophrenia: further evidence of orbitofrontal dysfunction. Schizophr. Res. 2007, 93:296-303.
77. Waltz J.A., et al. Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction. Biol. Psychiatry 2007, 62:756-764.
78. Wilson R.C., Doudna J.A. Molecular mechanisms of RNA interference. Annu. Rev. Biophys. 2013, 42:217-239.
79. Wilson R.I., et al. Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron 2001, 31:453-462.
80. Xu B., et al. Elucidating the genetic architecture of familial schizophrenia using rare copy number variant and linkage scans. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:16746-16751.
81. Yang M., Crawley J.N. Simple behavioral assessment of mouse olfaction. Curr. Protoc. Neurosci. 2009, 24. (editorial board, Jacqueline N. Crawley . [et al.]. Chapter 8, Unit 8).
82. Yang M., et al. Automated three-chambered social approach task for mice. Curr. Protoc. Neurosci. 2011, 26. (editorial board, Jacqueline N. Crawley . [et al.]. Chapter 8, Unit 8).
83. Zimmer A., et al. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:5780-5785.